skip to Main Content

About Aramchol

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid con­jugate. Aramchol is a first in class, orally active, liver tar­geted SCD – 1 mod­u­lator with a dual mode of action on liver fibrosis, down reg­u­lation of steatosis and a direct effect on Hepatic Stellate Cells (HSC’s), the human col­lagen pro­ducing cells. Aramchol has shown down reg­u­lation of liver steatosis and fibrosis in mul­tiple animal models (see also pub­li­cation section) demon­strating its effect on the three key pathologies of NASH: steatosis, inflam­mation and fibrosis. The effect of Aramchol on NASH pathologies in animals was trans­lated into humans in a phase IIa clinical study and is cur­rently being examined in the Phase IIb ARREST study (see also Clinical Devel­opment section). To date, over 400 patients have been exposed to Aramchol across 7 clinical trials. No safety and tol­er­a­bility signals have been iden­tified thus far. Aramchol has been granted Fast Track des­ig­nation status by the FDA for the treatment of NASH.


First-in-class, orally active, liver tar­geted SCD-1 mod­u­lator


Potent mech­anism with mul­tiple inter­vention points along the path­o­genic pathway


Effects in animal models into human ctrans­lated linical data

On Track For FDIC Approval

High safety margin and B/​R ratio

Tested By 400 People

~400 sub­jects exposed across 7 clinical trials

Fast Track

Fast Track Des­ig­nation for devel­opment of Aramchol for NASH granted by FDA

Back To Top